The 10,000 Handpieces No Patient Will Touch

Here's the opening: a surgical robotics company that sells single-use disposable instruments for prostate procedures ended fiscal 2025 with more than 10,000 of those instruments sitting in customers' closets. Not installed. Not used. Just there - bulk-purchased, discount-priced, and quietly sitting on shelves across the country.

That was weird.

The company, PROCEPT BioRobotics (NASDAQ: PRCT), makes the AquaBeam system - a robotically controlled waterjet device used to treat enlarged prostates. You can think of it as a razor-and-blades business. The robotic system is the razor, placed once at a hospital or surgery center for roughly $100,000 to $200,000. The handpiece is the blade: a single-use disposable that costs roughly $3,300 and gets consumed during each procedure. In a normal razor-and-blades model, the consumable sales are the recurring revenue engine, and the number of consumables sold is a pretty direct read on how much the underlying machine is actually being used.

The complaint alleges that PROCEPT told investors, repeatedly, that handpiece sales were in line with the number of procedures performed. It also alleges that the company said customers "tend to order as they need [a] product" and that the differential between handpiece sales and procedures had "remained relatively consistent." The whole valuation rested on handpiece revenue as a signal of growing utilization across the company's installed base of robotic systems.

Here's the part that makes this securities fraud instead of just a bad quarter: allegations now say PROCEPT had an undisclosed discount program that kicked in during the final weeks of each quarter, incentivizing customers to place bulk orders far beyond what their procedure schedules actually required. Handpiece orders were not tracking real-time demand. They were tracking calendar quarters and end-of-period incentives. The company was selling the same handpieces twice - once in Q1 at a discount, and again in the investor narrative as proof of growing adoption.

This is basically channel stuffing, dressed up as subscription-like recurring revenue. Channel stuffing is not exactly a new concept. It's the practice of shipping more product to distributors or customers than they can sell, counting it as revenue now, and hoping nobody notices the pipeline empty next quarter. In durable-goods businesses, it's easier to spot. You can count how many washing machines a retailer can realistically sell per month. In a single-use medical consumable business, where the company controls the data on how many procedures actually happen, the gap between orders and utilization is harder for outsiders to measure - until the company decides to start reporting both numbers side by side.

That disclosure came in stages, each one followed by a stock drop, because the company was slow to connect the dots that investors needed to see.

On August 6, 2025, PROCEPT announced fiscal Q2 results and handpiece unit shipments unexpectedly deteriorated. The stock fell 16% over two days, from $45.69 to $38.41.

On November 4, 2025, fiscal Q3 results brought a cut to annual handpiece guidance and management admitted some customers were "probably carrying too much" inventory. The stock fell another 10%.

Then on February 25, 2026 - the day that ends the class period - the full picture came out. PROCEPT disclosed that U.S. handpiece sales had materially exceeded procedures in every quarter since Q1 2023, that cumulative excess field inventory exceeded 10,000 units, and that U.S. handpiece sales had contracted roughly 30% sequentially, from 13,225 units in Q3 to 9,400 in Q4. Management also confirmed the company was eliminating the previously undisclosed bulk-order discount program that had been pulling future demand into current quarters. The stock fell 18% over two days, from $27.84 to $22.69.

By that point, the share price had already shed roughly 48% from the August 6, 2025 disclosure, and more than 75% from its class-period high. The stock trades around $18 today; the company ended fiscal 2025 with about $289 million in cash and a burn rate that puts a real question mark on how long the runway lasts.

The simplest model

The complaint - filed by a pension fund and captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation - focuses on disclosure. The core claim is that management made statements about handpiece sales being consistent with procedures while knowing that an undisclosed discount program was driving orders that had nothing to do with actual procedure volume. That's the securities fraud allegation.

But let's step back from the legal framing for a moment and think about the incentives. PROCEPT is a pre-profitability company burning roughly $95 million a year in net losses. Its valuation depends on investors believing that handpiece revenue is growing sustainably, which implies the installed base of robotic systems is being used more and more. If handpiece orders are actually just being pulled forward from future quarters through discounts, the revenue is real today but the growth story is borrowed. It's not fake revenue - it's revenue with a time machine.

There's a tiny dialogue that explains the whole machine:

Hospital purchasing manager: "I need 200 handpieces this quarter for procedures. But if you give me a bulk discount on 500, I'll take them now and use the rest over the next two quarters."

PROCEPT salesperson: "Here's the discount."